|Articles|May 15, 2003

BioPharm International-05-01-2003
Volume 16
Issue 5

Patent Law: Extracting Maximum Value from Your Patent Portfolio

Author(s)Rebecca Burton, Craig R. Kaufman, Anne-Marie Dinius

by Craig R. Kaufman, Orrick, Herrington & Sutcliffe LLP, Rebecca Burton, and Anne-Marie Dinius Your patent portfolio does not make money sitting in a file cabinet. Extracting its value requires both market surveillance and an effective litigation or licensing strategy.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 23 years ago

Article

Demonstrating the Consistency of Small Data Sets: Application of the Weisberg t-test for Outliers

over 23 years ago

Article

Sumeria to Satellites: Evolution of the Bioreactor

over 23 years ago

Article

A Statistical Method to Account for Plate-to-Plate Variability in Multiple-Plate Bioassays

over 23 years ago

Article

Inside Washington: Medication Safety in the Limelight

over 23 years ago

Article

Part 11 Is Not Going Away: The New Electronic Records Draft Guidance

over 23 years ago

Article

Survival Strategies: The Life Sciences Industry Turns to eLearning

over 23 years ago

Article

Analytical Advances: Collaborative Effort Results in Automated Cell Culture System

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

October 16th, 2026

BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding

Opus Genetics reports sustained vision gains with gene therapy, the FDA approves Roche’s Enspryng for at-home treatment of thyroid eye disease, and Estuary Biotherapeutics launches with $103 million to develop gene therapies for polycystic kidney disease.

Two researchers in lab coats, safety glasses, and blue gloves review data on a computer monitor in a laboratory, with racks of sample tubes and a microscope on the bench and a third researcher working in the background. | Image Credit: © DC Studio - stock.adobe.com

October 16th, 2026

FAQ: When Big Pharma Drops a Drug Candidate, Who Picks It Up?

When large pharmaceutical companies deprioritize drug candidates, smaller developers may license or acquire them, but due diligence, deal structure, and trial planning determine whether a program can move forward.

Close-up of a person’s eye with a hazel-green iris during an eye examination, with a beam of orange light falling across the eyelid and a white instrument forehead rest visible at the top of the frame. | Image Credit: © bradleyblackburn - stock.adobe.com

October 16th, 2026

Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3

Interim phase 1/2 data presented at Retina in Rio 2026 showed sustained visual improvements with Opus Genetics’ AAV8 gene therapy OPGx-LCA5 and improved retinal sensitivity with OPGx-BEST1 in inherited retinal diseases.

Close-up photograph of a wide-open human eye with a blue-gray iris flecked with gold, a dark pupil, and visible upper and lower eyelashes. | Image Credit: © bradleyblackburn - stock.adobe.com

October 16th, 2026

FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease

The FDA approved Roche's satralizumab (Enspryng), an IL-6 receptor-targeting monoclonal antibody, for adults with thyroid eye disease based on the Phase 3 SatraGO-1 and SatraGO-2 trials, giving patients the first at-home subcutaneous treatment option.

Unrecognizable female doctor holding graphic virtual visualization model of Kidneys organ in hands. Multiple virtual medical icons. | Image credit: © mi_viri - © mi_viri - stock.adobe.com

October 16th, 2026

Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy

EST-201 and EST-101 target the genetic root cause of ADPKD, a disease affecting more than 8 million people worldwide, with trials starting 2027-2028.

October 15th, 2026

Shift to In Vivo CAR T Will Reshape Facility Design, Says Arcadis’ Emily Heffernan

Emily Heffernan of Arcadis explains how facility scale, equipment, containment, and quality testing differ across ex vivo cell therapy, viral vector, and mRNA-LNP manufacturing.

October 15th, 2026

The BioPharm Brief: New Approvals, Biosimilar Competition, and Deeper Remission

FDA expands Anktiva’s bladder cancer indication, Alvotech and Advanz submit a proposed Eylea 8 mg biosimilar in Europe, and Lilly reports new remission data for Omvoh in inflammatory bowel disease.

Research and scanning eye, close-up photos, retinal diagnostics in ophthalmology | Image credit: © Анна Ковальчук - © Анна Ковальчук - stock.adobe.com

October 15th, 2026

Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid

AVT29, a proposed aflibercept biosimilar to Eylea 8 mg, could extend retinal disease treatment intervals to 16 weeks, versus 8 weeks today.

Patent Law: Extracting Maximum Value from Your Patent Portfolio

Articles in this issue

Related to this article

Trending on BioPharm International

Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid

Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals

Shift to In Vivo CAR T Will Reshape Facility Design, Says Arcadis’ Emily Heffernan

The BioPharm Brief: New Approvals, Biosimilar Competition, and Deeper Remission

FDA Grants Marengo’s Invikafusp Alfa Second Fast Track Designation in TMB-H Solid Tumors